Soleno Therapeutics Engagement at Upcoming Healthcare Conference
Soleno Therapeutics Engages at Notable Healthcare Conference
Soleno Therapeutics, Inc. (NASDAQ: SLNO), renowned for its commitment to developing innovative therapeutics for rare diseases, announced its participation in a prestigious healthcare conference. This opportunity for engagement comes as Soleno continues to make strides in the biopharmaceutical landscape.
Details of the Conference Participation
Management from Soleno Therapeutics is scheduled to take part in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference. This highly anticipated event will take place on a Thursday morning, providing a platform for the company's insights and updates.
Timing and Accessibility
The chat will commence at 9:00 AM Eastern Time. Interested stakeholders can tune in to the live audio webcast, which will also be available for replay. This will allow a wider audience to engage with Soleno's latest developments in real-time.
Understanding Soleno’s Mission
Soleno Therapeutics is dedicated to developing treatments that address the unique challenges posed by rare diseases. One of their flagship products in the pipeline, DCCR (diazoxide choline) extended-release tablets, is aimed at treating Prader-Willi syndrome (PWS). The New Drug Application (NDA) for DCCR is currently undergoing review by the FDA, which has granted it Priority Review status due to its potential significance.
The Importance of Rare Disease Treatments
Addressing rare diseases is critical in the realm of healthcare, as these conditions often do not have many treatment options available. Soleno’s focus on creating therapies to manage such diseases is notable. Their research and development efforts highlight the importance of innovation in providing solutions to underserved patient populations.
Company Information and Resources
For those seeking further information about Soleno Therapeutics and their initiatives, the company maintains an informative website that includes comprehensive details about their product pipeline and corporate updates.
Contact Information
For inquiries, the corporate contact for Soleno is Brian Ritchie from LifeSci Advisors, reachable at 212-915-2578. Engaging with investors and the public is an essential aspect of their outreach strategy, ensuring transparency and open communication.
Frequently Asked Questions
What is the purpose of Soleno Therapeutics at the conference?
Soleno Therapeutics aims to share insights and updates about their innovative therapeutics, particularly for rare diseases.
When will the fireside chat take place?
The chat is scheduled for 9:00 AM Eastern Time on a Thursday during the conference.
What is DCCR and its significance?
DCCR is Soleno's lead candidate aimed at treating Prader-Willi syndrome, currently under FDA review with Priority Review status.
How can stakeholders access the conference?
Stakeholders can access the conference through a live audio webcast, which will also be available for replay afterwards.
Who can be contacted for more information about Soleno?
Brian Ritchie from LifeSci Advisors is the corporate contact for inquiries related to Soleno Therapeutics.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.